Challenges to estimating vaccine impact using hospitalization data  by Schuck-Paim, Cynthia et al.
Vaccine 35 (2017) 118–124Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vaccineChallenges to estimating vaccine impact using hospitalization datahttp://dx.doi.org/10.1016/j.vaccine.2016.11.030
0264-410X/ 2016 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author at: 65 Pine Street, Suite 1, Portland, ME 04102, United
States.
E-mail address: cschuck@sageanalytica.com (C. Schuck-Paim).Cynthia Schuck-Paim a,⇑, Robert J. Taylor a, Lone Simonsen b, Roger Lustig a, Esra Kürüm c,d,
Christian A.W. Bruhn c, Daniel M. Weinberger c
a Sage Analytica, Portland, ME, United States
bDepartment of Global Health, Milken Institute School of Public Health, George Washington University, Washington, DC, United States
cDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States
dDepartment of Statistics, University of California, Riverside, CA, United Statesa r t i c l e i n f o
Article history:
Received 18 August 2016
Received in revised form 4 November 2016
Accepted 8 November 2016
Available online 26 November 2016
Keywords:
Vaccines
Hospitalization
Health impact assessment
Pneumococcal vaccines
Pneumonia
Confounding factors
Bias
Delivery of health care
Brazil
Latin America
Pneumococcus
Pneumococcal conjugate vaccines
Observational studies
Public healtha b s t r a c t
Because the real-world impact of new vaccines cannot be known before they are implemented in national
programs, post-implementation studies at the population level are critical. Studies based on analysis of
hospitalization rates of vaccine-preventable outcomes are typically used for this purpose. However,
estimates of vaccine impact based on hospitalization data are particularly prone to confounding, as
hospitalization rates are tightly linked to changes in the quality, access and use of the healthcare system,
which often occur simultaneously with introduction of new vaccines. Here we illustrate how changes in
healthcare delivery coincident with vaccine introduction can influence estimates of vaccine impact, using
as an example reductions in infant pneumonia hospitalizations after introduction of the 10-valent pneu-
mococcal conjugate vaccine (PCV10) in Brazil. To this end, we explore the effect of changes in several
metrics of quality and access to public healthcare on trends in hospitalization rates before (2008–09)
and after (201112) PCV10 introduction in 2010. Changes in infant pneumonia hospitalization rates fol-
lowing vaccine introduction were significantly associated with concomitant changes in hospital capacity
and the fraction of the population using public hospitals. Importantly, reduction of pneumonia hospital-
ization rates after PCV10 were also associated with the expansion of outpatient services in several
Brazilian states, falling more sharply where primary care coverage and the number of health units offer-
ing basic and emergency care increased more. We show that adjustments for unrelated (non-vaccine)
trends commonly employed by impact studies, such as use of single control outcomes, are not always suf-
ficient for accurate impact assessment. We discuss several ways to identify and overcome such biases,
including sensitivity analyses using different denominators to calculate hospitalizations rates and meth-
ods that track changes in the outpatient setting. Employing these practices can improve the accuracy of
vaccine impact estimates, particularly in evolving healthcare settings typical of low- and middle-income
countries.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In recent decades, the use of vaccines against infectious diseases
of global importance has grown substantially. Efficacy is always
assessed in pre-licensure trials before regulators approve a new
vaccine. However, the real-world impact of vaccines can be greater
or smaller than efficacy due to indirect factors such as herd immu-
nity and serotype replacement. Moreover, pre-licensure trials are
performed under idealized conditions and often exclude certain
high-risk individuals. Therefore, studies that assess the impact ofnewly introduced vaccines on disease rates at the population level
are critical.
In real-world populations, however, nothing is static. Estimat-
ing vaccine effects with accuracy is always complicated by other
changes that occur in the population around the time the vaccine
is introduced. Unrelated trends can be particularly pronounced in
rapidly developing countries, where the introduction of a new vac-
cine often occurs concomitant with unrelated improvements in
public health.
Because population-based surveillance data are rarely available
on a large scale, and laboratory confirmation of the causative
pathogen is often not possible, vaccine impact evaluations often
rely on proxy measures of disease rates at the community level.
Hospital admission data have been widely used for that purpose,
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same population before and after vaccine introduction [1–3].
Electronic hospitalization databases are effective tools for pub-
lic health research, surveillance and planning, providing systematic
and low-cost information about large populations. However, hos-
pitalization data are also prone to specific biases and confounding
that can affect estimates of vaccine impact, as admission rates are
closely linked to changes in broad societal trends that affect not
only biological susceptibility to disease, but also healthcare deliv-
ery itself.
Here we investigate how changes in healthcare delivery influ-
ence estimates of vaccine impact by exploring the association
between hospitalization rates and healthcare access and quality.
As a case study, we focus on changes in infant hospitalization rates
for pneumonia after introduction of the 10-valent pneumococcal
conjugate vaccines (PCV10) in Brazil in 2010.
Our results indicate that commonly employed adjustments are
not always sufficient to control for changes in hospitalization rates
unrelated to vaccine introduction, particularly in evolving health-
care settings. We discuss several ways to identify and address
these biases.2. Methods
To examine how changes in healthcare use and delivery affect
hospitalization rates, we calculated several metrics of healthcare
utilization, quality, and access before and after PCV10 introduction.
We then explored how changes in these metrics were associated
with simultaneous changes in crude hospitalization rates for pneu-
monia and comparison outcomes. We focused the analysis on
infants <12 months, the primary group targeted for vaccination.2.1. Data on hospitalizations
In Brazil, access to the public health service is, in principle,
universal, and comprehensive data are available on people who
receive public care (82% of the population in 2012). We obtained
de-identified, age-stratified monthly data on hospitalizations
(Jan2003–Dec2013) from the Unified Health System (SIH-SUS,
Ministry of Health; [4]), which maintains a nationwide database
that records all hospitalizations paid by the government. This
database has been shown to record pneumonia hospitalization
incidence in infants as reliably as prospectively collected primary
hospitalization data [5].
To minimize the number of nosocomial pneumonia cases
included in the time series, we excluded hospitalizations
associated with ‘‘treatment packages”—sets of services, supplies
and procedures—unrelated to community-acquired pneumonia
(Table S1). We also excluded records in which the ‘‘length of stay”
field was inconsistent with the discharge and admission dates
(representing instances where a patient was immediately readmit-
ted following discharge). We also excluded records from union,
university, and self-financed hospitals, as those did not contribute
consistently to the database.2.2. Inpatient healthcare delivery: use of public hospitals and hospital
capacity
Although access to public health is universal, some citizens opt
for a privately financed tier of care perceived to offer better quality
and faster access. To determine the size of the infant population
actually using the public system (SUS) and thus represented in
the hospitalization database, we subtracted the number of infants
enrolled in private insurance plans offering hospitalizationcoverage [6] from the total infant population (Brazilian Institute
of Geography and Statistics).
We considered hospital bed supply (hospital beds available in
SUS; [7]) as a measure of hospital capacity.
2.3. Healthcare delivery: outpatient care access and quality
Because many pneumonia hospitalizations are preventable by
appropriate care and management, improvements in outpatient
services at the time of PCV10 introduction might reduce pneumo-
nia hospitalizations. We focused on three metrics: (i) the number
of health units offering basic healthcare services [8]; (ii) the per-
centage of the population appropriately covered by health teams
[9], defined by the government as the number of teams working
in an area multiplied by 3000 (based on the recommendation that
each team can provide proper care for 3000 people) and divided by
the population living in the area, and (iii) the total number of UPAs
(Unidades de Pronto Atendimento; [10]), i.e. emergency care units
placed in many municipalities starting in 2008; UPAs are designed
to reduce the demand for hospital services, and are equipped to
treat cases of higher complexity than basic healthcare units.
We also examined potential changes in the quality of outpatient
care by analyzing trends in rates of ‘‘potentially avoidable hospital-
izations” (PAHs), a group of disease outcomes often used as an
indicator of primary care quality; we used the list of PAHs adopted
by the Brazilian government (Table S2). In theory, improvements in
prevention and early disease management at the outpatient setting
should lower PAH rates.
2.4. PCV10 uptake
Brazil introduced PCV10 in its National Immunization Program
(PNI) in March 2010. To estimate PCV10 coverage, we calculated
the percentage of eligible infants (6–23 months) who had at least
the 3 recommended routine doses (at 2, 4 and 6 months) using
the age-cohort method described in [11]. Data on doses adminis-
tered by state, month and age was provided by PNI [12]; live birth
statistics (SINASC, [13]) were used to estimate rates. Nationally,
PCV10 coverage reached 33%, 76% and 89% by December 2010,
2011 and 2012, respectively.
2.5. Data analysis
We first examined the consistency of ICD10 pneumonia coding
from 2003 to 2012. We found that the pattern of codes assigned for
many disorders changed dramatically in January 2008, coincident
with substantial changes in the system used to reimburse hospi-
tals, which relaxed the specificity of ICD10 reporting requirements.
For example, the frequency of pathogen-specific codes such as J13
(pneumococcal pneumonia) and J14 (H. influenzae pneumonia) fell
sharply, while the number of J18 codes (pneumonia, organism
unspecified) rose (Fig. S1). We therefore limited our pre-post anal-
ysis to the period starting in January 2008.
We next tested the association between changes in hospitaliza-
tion rates before and after PCV10 introduction and concomitant
changes in the healthcare metrics previously described. Changes
in hospitalization rates were estimated as in [14], by calculating
the ratio (incidence rate ratio, or IRR) between the average annual
incidence rate two years post-PCV (201112) and two years pre-
PCV10 (2008–09), with their corresponding 95% confidence inter-
vals [15]. The association between IRR and relative changes in
healthcare metrics were tested with Pearson and Spearman
correlations.
Because our aim was to illustrate the effect of broader changes
in healthcare delivery on simultaneous changes in crude rates of
hospitalization rather than to estimate vaccine impact itself, we
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models or methods other than the calculation of IRRs. IRRs
reported here should therefore not be taken as estimates of
PCV10 impact; they are only used to illustrate the effect of the
potentially confounding trends discussed on hospitalization rates
for pneumonia.
Pre-post PCV10 IRR estimates, calculated as described above,
were computed for all-cause pneumonia (ICD10 J12-18), respira-
tory disease (J00-99), infectious diseases other than diarrhea
(A10-B99), which was excluded to avoid confounding by rotavirus
vaccine introduction in Brazil, and all hospitalizations (all causes).
We conducted the analyses both at a national and state level, to
take advantage of variability in the timing at which the states
introduced changes in the health system.
We also analyzed whether putative associations between
improvements in healthcare and reductions in hospitalizations
for pneumonia were a by-product of differences in PCV10 coverage
among states, given that in states where the health system
improved more, PCV10 coverage may have been higher, driving
pneumonia hospitalizations down. To this end, we tested the asso-
ciation between PCV10 coverage (at December 2010, 2011 and
2012) and IRRs for all-cause pneumonia (Pearson correlation).
We also tested whether PCV10 coverage was associated with
changes in healthcare delivery.
Data extraction and processing were performed with SAS 9.3.
IRR estimates were calculated in Excel, and all correlations with
Minitab v.17.3.1.
3. Results
3.1. Effect of changes in the population using hospitals in the public
system
Estimates of vaccine impact depend on how well the denomina-
tor used to calculate hospitalization rates represents the popula-
tion using hospitals. From 2008 to 2012, the infant population
dropped by 7% (from 3.1 to 2.8 million infants). Moreover, the per-
centage of Brazilian infants who participated in the SUS system,
and who thus contributed to the data, fell from 85% to 83% (from
2.6 to 2.3 million infants). When using the total Brazil population
of infants as the denominator, the IRR for pneumonia was 0.89
(95%CI 0.88–0.90)—an 11.3% drop nationwide, but only 0.92 (95%
CI 0.91–0.93)—a 7.8% drop—when the SUS population was used
as the denominator (Table 1). That represents a 30.8% difference
between estimates. In all regions, denominating pneumonia hospi-
talizations by the SUS population rather than the total population
reduced the magnitude of the drop in hospitalization rates
(Table 1); the difference was greatest in the Southeast, with the
estimated drop almost halving when using SUS population (from
11.5 to 6.5%).
3.2. Effect of changes in inpatient healthcare delivery systems
Public health care (SUS) is provided in Brazil through both
nonprofit (government-owned and philanthropic) and for-profitTable 1
Effect of population denominator on IRR estimates of pneumonia hospitalizations (J12-18
Regions IRR (95%CI) [% decline]
Denominator: total population [A] Denominator SUS population [B
National 0.89 (0.88–0.90) [11.3%] 0.92 (0.91–0.93) [7.8%]
North 0.89 (0.87–0.91) [10.9%] 0.90 (0.88–0.92) [10.2%]
Northeast 0.89 (0.88–0.91) [10.7%] 0.92 (0.90–0.93) [8.1%]
Centre-West 0.85 (0.82–0.88) [15.2%] 0.89 (0.86–0.92) [11.0%]
Southeast 0.88 (0.87–0.90) [11.5%] 0.94 (0.92–0.95) [6.5%]
South 0.85 (0.83–0.86) [15.8%] 0.86 (0.84–0.88) [13.8%]hospitals (under contract to provide beds to the public system).
Nationally, the supply of public hospital beds provided through
both for-profit and nonprofit hospitals dropped by approximately
5% from 2008 to 2012 (from 2.2 to 2.1/1000 population). For each
Brazilian state, we plotted the change in the number of beds avail-
able per 1000 infants against IRR. We found that reductions in hos-
pitalization rates for pneumonia were sharper in states where bed
loss was more pronounced (Fig. 1). Strong associations between
bed loss and IRR were also observed for the other outcomes, partic-
ularly all-cause hospitalizations (Fig. 1).
Changes in public bed supply, however, were different among
for-profit and non-profit hospitals. In for-profit hospitals, beds
made available to SUS fell 13% from 2008 to 12 (from 0.89 to
0.77 beds/1000), but increased 5% among non profit hospitals, from
1.29 to 1.36 beds/1000. We hypothesized that if the number of
available beds affects admissions, declines in hospitalization rates
would be greater in for-profit hospitals. We found this to be the
case (Table 2), with a greater decline in pneumonia hospitaliza-
tions in for-profit (IRR = 0.70; 95%CI 0.68–0.71) than nonprofit
facilities (IRR = 0.98; 95%CI 0.97–0.99). We found a similar result
for all respiratory outcomes (J00-99; Table 2), suggesting that IRR
differences between for-profit and non-profit hospitals were not
due to differences in risk factors for pneumonia or PCV coverage
between them. There was no significant association between bed
loss and PCV10 coverage (p > 0.05).
Because all-cause hospitalizations track the total capacity of the
hospitalization system, we next calculated IRRs for pneumonia and
respiratory disease using the total number of hospitalizations as
the denominator. Overall, there were large differences in estimated
IRRs between the analysis using SUS population and total hospital-
izations as the denominator (Table 2). In the latter case, IRR differ-
ences between for-profit and non-profit were substantially
reduced or were not significant.3.3. Effect of changes in outpatient healthcare delivery system
From Jan-2008 to Dec-2012, the proportion of the population
covered by appropriate primary care teams (see Methods)
increased nationwide from 64% to 67%. Similarly, the number of
outpatient units providing basic care services increased from
96,000 to 115,000 units. At the same time, the proportion of
hospitalizations classified as potentially avoidable (PAHs, an
indicator of primary care quality; see Methods) relative to total
hospitalizations fell from 30% to 25%.
In line with the expectation that most pneumonia hospitaliza-
tions are potentially avoidable given appropriate primary care, rate
reductions for pneumonia were larger in those states where
primary care coverage increased more (Fig. 2), and in states that
experienced a larger growth in the number of units providing basic
healthcare services (Fig. 2). Significant correlations (Pearson;
r = 0.34 to 0.49; p < 0.05) in the same direction were also found
for respiratory disease (J00-99), and all-cause hospitalizations, but
not for infectious diseases (A10-B99). These findings were not
driven by differences in PCV10 coverage among states, as PCV10) in 2011–12 vs. 2008–09 for children <12 months of age.
% difference in estimated decline [(A  B)/A] ⁄ 100 % infants using SUS
] 2008–09 2011–12
30.8% 85.0% 81.7%
5.9% 93.1% 92.4%
24.2% 93.4% 90.7%
27.7% 91.4% 86.9%
43.9% 74.6% 70.5%
12.5% 84.0% 82.0%
Table 2
The effect of using SUS population and all-cause hospitalizations as the denominator when calculating incidence rate ratios (IRR) (2011–12 vs. 2008–09 pneumonia
hospitalization rates) in nonprofit and for-profit hospitals providing care to SUS patients.
Disease outcome Effect of changes in bed availability
IRR (95% CI) in nonprofit
hospitals in SUS system
IRR (95% CI) in for-profit
Hospitals in SUS system
Effect of denominator used
to calculate IRR
SUS population as
denominator
Pneumonia (J12-18) 0.98 (0.97–0.99) 0.70 (0.68–0.71)
All Respiratory (J00-99) 1.04 (1.03–1.05) 0.71 (0.70–0.72)
All-cause hospitalizations
as denominator
Pneumonia (J12-18) 0.87 (0.86–0.88) 0.92 (0.90–0.94)
All Respiratory (J00-99) 0.92 (0.91–0.93) 0.92 (0.90–0.94)
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described.
We examined whether the increasing availability of UPAs (new
emergency outpatient units; see Methods) was associated with a
reduction in pneumonia hospitalization rates following PCV10
introduction. We found that in states that created more UPAs up
to 2012, rate reductions in pneumonia hospitalizations were also
greater (Fig. 2).
4. Discussion
Observational studies of trends in hospitalizations have been
widely and productively used to estimate disease burden and the
impact of vaccines [16–20]. However, attributing changes in hospi-
talization rates before and after the start of an intervention specif-
ically to that intervention can be challenging, and may lead to an
over- or under-estimation of benefits in countries where the
healthcare system is itself evolving. Because such changes often
occur rapidly in low- and middle-income countries, one must be
particularly cautious in such settings, especially if the expected
impact of a vaccine is relatively modest. In Table 3 we summarize
prior studies of PCV impact on all-cause pneumonia hospitaliza-
tions in Latin America, and their use of different practices that
might help to identify or adjust for such biases.
In Brazil, we found a positive association between the supply of
hospital beds and rates of hospitalization for pneumonia; others
have published similar findings [21,22]. This suggests that
hospitals were operating at full capacity, an observation corrobo-
rated by a recent report showing that most public hospitals inBrazil cannot meet demand for services [23]. Indeed, the 2.2 beds
per 1000 persons in 2008 was less than half the European average
of 5.5 beds/1000 that same year [24].
Interpreting trends in disease rates inferred from hospitaliza-
tion data is difficult when hospitals are running at or over
capacity. In such circumstances, higher community-acquired
disease rates may not translate into proportional increases in
hospitalizations because hospitals would not be able to meet
the increased demand. Conversely, lowered disease rates could
be partially or even fully masked, as hospitalization databases
have no records of potential patients turned away due to lack
of available beds.
Using all-cause hospitalizations to denominate hospitalization
rates can help control for changes in hospital capacity. Addition-
ally, all-cause hospitalizations can track and adjust for changes in
the population using target hospitals – such as those caused by
the migration to private insurance. However, if hospitals are
operating at full capacity, and the target disease and/or age group
studied has a different admission priority compared to other
groups (e.g. pneumonia is high-priority in Brazil), denomination
by all-cause hospitalizations can also result in biased estimates.
For example, if the incidence of community-acquired pneumonia
cases is unchanged (i.e. pneumonia cases decline proportionally
with decreases in population size), hospital beds freed from pneu-
monia cases will be used for other conditions. Accordingly, the pro-
portion of pneumonia over all-cause hospitalizations will reduce
due to such non-vaccine related changes. Therefore, considering
changes in both population size and all-cause hospitalizations
when hospitals operate over capacity is critical.
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122 C. Schuck-Paim et al. / Vaccine 35 (2017) 118–124Importantly, denomination by either all-cause hospitalizations
or population does not prevent introduction of bias caused by
changes in outpatient services [25]. In Brazil, expansion of outpa-
tient care services was associated with reduced hospitalizations
for pneumonia and other outcomes, indicating that changes in this
setting can be an important source of confounding. For example, in
2006 Brazil introduced a nationwide program called ‘Pact for
Health’. One of its goals was to reduce diarrhea and pneumonia
deaths in young children. The program created local committees
to monitor child mortality and trained medical staff in proper
treatment of these diseases. These measures likely added to the
effect of immunization programs, such as the introduction of the
rotavirus vaccine in the same year.
One way to identify biases resulting from changes in outpatient
care is the analysis of outcomes that are affected by factors that also
affect the vaccine target, but are themselves unaffected by the vac-
cine [26]. Since changes in outpatient care can introduce bias, such
comparison outcomes should be similarly sensitive to such
changes. Because PAHs are by design sensitive to primary care
[27–29], it may be possible to use trends in PAH rates, or appropri-
ate subsets, as a proxy for changes in primary care quality. Alterna-
tively, ‘‘synthetic controls” has been shown to provide a data-drivensolution to control for unrelated trends in disease rates [30]. In this
approach, time series of outcomes assumed to be unaffected by the
vaccine are weighted and combined into a single composite time
series depending on their fit to the time series of interest
(e.g., pneumonia) before vaccine introduction. The composite
‘‘synthetic control” is then calculated by applying the weights from
the pre-vaccine period to the outcome incidences in the post-
vaccine period, producing a counterfactual estimate of disease rates
had no vaccine been in use. This method does not require a priori
qualitative decisions on what constitutes an appropriate control,
which can itself introduce bias. Another option is to analyze inpa-
tient and outpatient trends simultaneously (e.g. [31]). If the vaccine
works as expected, and disease etiology is not different between
these settings, the burden of both hospitalizations and outpatient
visits for the vaccine target should fall.
Of the studies summarized in Table 3, three [32–34] did not
seek to adjust for secular trends, potential biases and confounding.
Seven addressed potential biases arising from changes in inpatient
care by using all-cause hospitalizations as a denominator [35–37],
analyzing control outcomes possibly with similar admission prior-
ity [20,31,35] or directly analyzing hospital capacity [38]. Similarly,
five used controls potentially sensitive to primary care changes
Table 3
Summary of studies of PCV impact on hospitalization rates for childhood pneumonia in Latin American countries.
Country Period studied
(Pre/Post)
Age
(months)
Nature of data Geographic
subdivision
Denominator Analyzed
Secular
Trends?
Analyzed
Hospital
Capacity?
Used
control
outcomes?
Analyzed
outpatient
setting?
Reference
Brazil 2005–09/2011 2–24 Prospective 5 Municipalities Live births Yes No Yesb No [20]
2002–09/20111–12 <48 Administrative National Population Yes No Yesc No [41]
2007–09/2011–12 2–35 Prospective 1 Municipality Population Yes Yes No No [38]
2007–09/2011–13 <12 Administrative 26 Municipalities Population No No No No [32]
Uruguay 2001–04/2009–11 <60 Prospective 4 Hospitals Population No No No No [33]
2001–04/09–12 <168 Prospective 2 Municipalities Population No No No No [34]
2003–07/2012 <168 Prospective 1 Hospital ACHa No No No No [35]
2005–07/2009 <168 Prospective 1 Hospital ACHa No No Yesd No [36]
Panama 2007–08/2008–10 <60 Administrative 1 Hospital ACHa No No No No [37]
Nicaragua 2008–10/2011–12 <24 Administrative 107 Health Units Population No No Yese Yes [31]
Peru 2006–08/ 2011–12 <12 Administrative National Population Yes No No Yes [39]
Argentina 2003–05/2012–13 <60 Prospective 2 Hospitals Population No No No Yes [40]
a All-cause hospitalizations.
b Non-respiratory disease & bronchiolitis.
c Non-respiratory disease.
d Acute gastroenteritis.
e Diarrhea.
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secular trends [20,38,39,41] and single control outcomes
[20,31,36,41] can help control biases, but may not have been suffi-
cient to control them completely. For example, the potential reduc-
tion in pneumonia hospitalizations resulting from the creation of
over 500 UPAs in 2010–2012 (just after PCV10 introduction in Bra-
zil) may not be captured by these adjustments. Other unrelated
events may also affect hospitalization rates in the pre- (e.g., 2009
influenza pandemic) or post-PCV periods if not properly adjusted.
In conclusion, caution is needed when attributing changing
trends in hospitalization rates to vaccines. We suggest that in addi-
tion to considering secular trends, impact studies based on hospi-
talization data present sensitivity analyses showing the effect of
using various denominators, adjust for the potential effect of
changes in both the inpatient and outpatient settings and use com-
parison outcomes that also share similar hospital admission prior-
ity and sensitivity to primary care changes with the target disease.
These practices would strengthen efforts to understand how vacci-
nes translate into reductions of disease burden, especially where
cost-effective interventions are most needed.
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